Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression

New Insights on OX40 in the Control of T Cell Immunity and Immune Tolerance In Vivo

(2011) X. Xiao et al.   JOURNAL OF IMMUNOLOGY

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2

(2010) Silvia Piconese et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo

(2009) William L. Redmond et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Foxp3-Dependent MicroRNA155 Confers Competitive Fitness to Regulatory T Cells by Targeting SOCS1 Protein

(2009) Li-Fan Lu et al.   IMMUNITY

OX40 costimulation can abrogate Foxp3+regulatory T cell-mediated suppression of antitumor immunity

(2009) Naomi Kitamura et al.   INTERNATIONAL JOURNAL OF CANCER

In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

(2009) Kylie E. Webster et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Thymic OX40 Expression Discriminates Cells Undergoing Strong Responses to Selection Ligands

(2009) M. Klinger et al.   JOURNAL OF IMMUNOLOGY

Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates

(2008) Surojit Sarkar et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In vivo identification of novel STAT5 target genes

(2008) B. Basham et al.   NUCLEIC ACIDS RESEARCH